S&P 500   4,594.62
DOW   34,899.34
QQQ   391.20
Ship's master said he spent 50 hours sleepless before crash
Russia jails 5 people over coal mine disaster that killed 51
8 Outside the Box Strategies for Successful Brand Management
South African scientists brace for wave propelled by omicron
COVID variant spreads to more countries as world on alert
1 injured in Black Friday shooting at Washington state mall
News crew guard dies after being shot in attempted robbery
S&P 500   4,594.62
DOW   34,899.34
QQQ   391.20
Ship's master said he spent 50 hours sleepless before crash
Russia jails 5 people over coal mine disaster that killed 51
8 Outside the Box Strategies for Successful Brand Management
South African scientists brace for wave propelled by omicron
COVID variant spreads to more countries as world on alert
1 injured in Black Friday shooting at Washington state mall
News crew guard dies after being shot in attempted robbery
S&P 500   4,594.62
DOW   34,899.34
QQQ   391.20
Ship's master said he spent 50 hours sleepless before crash
Russia jails 5 people over coal mine disaster that killed 51
8 Outside the Box Strategies for Successful Brand Management
South African scientists brace for wave propelled by omicron
COVID variant spreads to more countries as world on alert
1 injured in Black Friday shooting at Washington state mall
News crew guard dies after being shot in attempted robbery
S&P 500   4,594.62
DOW   34,899.34
QQQ   391.20
Ship's master said he spent 50 hours sleepless before crash
Russia jails 5 people over coal mine disaster that killed 51
8 Outside the Box Strategies for Successful Brand Management
South African scientists brace for wave propelled by omicron
COVID variant spreads to more countries as world on alert
1 injured in Black Friday shooting at Washington state mall
News crew guard dies after being shot in attempted robbery
OTCMKTS:ABSCF

AB Science Stock Forecast, Price & News

$14.00
0.00 (0.00%)
(As of 11/24/2021 12:00 AM ET)
Add
Compare
Today's Range
$14.00
▼
$14.00
50-Day Range
$14.00
▼
$16.10
52-Week Range
$8.65
▼
$26.70
Volume
N/A
Average Volume
998 shs
Market Capitalization
N/A
P/E Ratio
N/A
Dividend Yield
N/A
Beta
N/A
View Price History Chart DataSkip Price History Chart
30 days | 90 days | 365 days | Advanced Chart
Receive ABSCF News and Ratings via Email

Sign-up to receive the latest news and ratings for AB Science and its competitors with MarketBeat's FREE daily newsletter.


AB Science logo

About AB Science

AB Science SA engages in the research, development, and sales of protein kinase inhibitor drugs. It develops pharmaceutical products for the treatment of cancer, neurological, and inflammatory diseases. The firm's pipeline includes Masitinib and AB8939. The company was founded by Alain Moussy and Jean-Pierre Kinet on July 11, 2001 and is headquartered in Paris, France.

Headlines

AB Science received FDA authorization to initiate Phase 1/II trial of AB8939 in the treatment of acute myeloid leukemia
November 22, 2021 |  finance.yahoo.com
AB Science received authorization from the FDA to resume patient enrollment in the confirmatory Phase 3 study of masitinib (AB19001) in patients with ALS
November 18, 2021 |  finance.yahoo.com
AB Science (OTCMKTS:ABSCF) Trading Down 4.9%
November 9, 2021 |  americanbankingnews.com
AB Science granted authorization from the French Health Authority (ANSM) to initiate a study of AB8939 in the treatment of Acute Myeloid Leukemia (AML)
October 18, 2021 |  finance.yahoo.com
AB Science receives FDA authorization to start clinical development program of masitinib in mast cell activation syndrome (MCAS)
October 4, 2021 |  finance.yahoo.com
AB Science today reports its revenues for the first half of 2021 and provides an update on its activities
September 30, 2021 |  finance.yahoo.com
AB Science receives regulatory authorization to commence a second Phase 2 Covid-19 study
September 28, 2021 |  finance.yahoo.com
AB Science receives Health Canada approval letter to commence Phase I/II trial of AB8939 in the treatment of Acute Myeloid Leukemia (AML)
September 22, 2021 |  finance.yahoo.com
AB Science announced that an abstract on the long-term survival of masitinib in ALS has been selected for a platform presentation at the Annual Meeting of the Spanish Society of Neurology
September 20, 2021 |  finance.yahoo.com
AB Science announced today that it has received authorization to resume patient enrollment in the phase 2 masitinib study of COVID-19 (AB20001)
September 16, 2021 |  finance.yahoo.com
AB Science announced that it has received new authorizations to resume patient enrollment in its Phase 3 studies of masitinib
September 14, 2021 |  finance.yahoo.com
AB Science announced today that results from masitinib study AB12003 in prostate cancer have been presented at the 2021 American Urological Association
September 13, 2021 |  finance.yahoo.com
AB Science announced today that latest clinical data on long-term survival analyses in ALS will be presented at the 2021 symposium on ALS/MND
September 2, 2021 |  finance.yahoo.com
See More Headlines

Industry, Sector and Symbol

Stock Exchange
OTCMKTS
Industry
Drug Manufacturers—Specialty & Generic
Sub-Industry
N/A
Sector
Medical
Current Symbol
OTCMKTS:ABSCF
Previous Symbol
CUSIP
N/A
CIK
N/A
Web
www.ab-science.com
Phone
(314) 720-0014
Fax
N/A
Employees
93
Year Founded
N/A

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
N/A
Price / Book
N/A

Profitability

EPS (Most Recent Fiscal Year)
N/A
Net Income
N/A
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
N/A
Return on Assets
N/A

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
N/A
Quick Ratio
N/A

Price-To-Earnings

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A

Miscellaneous

Outstanding Shares
N/A
Free Float
N/A
Market Cap
N/A
Optionable
Not Optionable

MarketRank™

Overall MarketRank™

1.00 out of 5 stars

Analyst Opinion: 0.0Community Rank: 5.0Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -












AB Science (OTCMKTS:ABSCF) Frequently Asked Questions

Is AB Science a buy right now?

1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for AB Science in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" AB Science stock.
View analyst ratings for AB Science or view top-rated stocks.

Who are AB Science's key executives?

AB Science's management team includes the following people:
  • Alain Moussy, Chairman & Chief Executive Officer
  • Laurent Guy, Chief Financial Officer
  • Antonello Cervone, Director-Information Technology
  • Christian Fassotte, Global Chief Medical Officer
  • Véronique Gélébart, Head-Clinical Operations & Clinical Development

What is AB Science's stock symbol?

AB Science trades on the OTCMKTS under the ticker symbol "ABSCF."

How do I buy shares of AB Science?

Shares of ABSCF can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is AB Science's stock price today?

One share of ABSCF stock can currently be purchased for approximately $14.00.

How many employees does AB Science have?

AB Science employs 93 workers across the globe.

What is AB Science's official website?

The official website for AB Science is www.ab-science.com.

Where are AB Science's headquarters?

AB Science is headquartered at 3, Avenue George V, Paris, Ile-de-France 75008.

How can I contact AB Science?

AB Science's mailing address is 3, Avenue George V, Paris, Ile-de-France 75008. The company can be reached via phone at (314) 720-0014.


This page was last updated on 11/28/2021 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here

As Featured By:

MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

Twitter Facebook StockTwits

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.